BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2025 5:47:38 AM | Browse: 58 | Download: 119
 |
Received |
|
2024-08-10 10:45 |
 |
Peer-Review Started |
|
2024-08-10 10:45 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-11-10 03:08 |
 |
Revised |
|
2024-11-22 15:51 |
 |
Second Decision |
|
2025-01-08 02:37 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-01-08 06:45 |
 |
Articles in Press |
|
2025-01-08 06:45 |
 |
Publication Fee Transferred |
|
2024-11-26 04:40 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-01-17 01:08 |
 |
Publish the Manuscript Online |
|
2025-01-23 05:47 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Behavioral Sciences |
Manuscript Type |
Basic Study |
Article Title |
Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Jing-Jing Wang, Yi-Hong Fan, Wan-Ting Cao, Rong Huang, Xin-Yi Yao and Meng-Lin Li |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Zhejiang Provincial Administration of Traditional Chinese Medicine |
2021ZA057 |
|
Corresponding Author |
Yi-Hong Fan, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yhfansjr@163.com |
Key Words |
Wuling powder; Ulcerative colitis; Depression; Brain-derived neurotrophic factor; Brain-derived neurotrophic factor precursor |
Core Tip |
A common psychological problem in patients with ulcerative colitis is varying degrees of depression, which can cause the patient’s condition to worsen. Wuling powder is widely used to treat anxiety, depression, insomnia and headache. Previous studies have found that the balance between brain-derived neurotrophic factor (BDNF) precursor/p75 neurotrophin receptor/sortilin and BDNF/tropomyosin receptor kinase B signalling is essential for maintaining brain homeostasis and preventing the development of depressive behaviours. Our study suggests that Wuling powder may play an antidepressant role by regulating the balance of the BDNF precursor/p75 neurotrophin receptor/sortilin and BDNF/tropomyosin receptor kinase B signalling pathways. Moreover, Wuling powder combined with mesalazine can further relieve intestinal inflammation in mice with ulcerative colitis and depression. |
Publish Date |
2025-01-23 05:47 |
Citation |
<p>Wang JJ, Fan YH, Cao WT, Huang R, Yao XY, Li ML. Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression. <i>World J Gastroenterol</i> 2025; 31(8): 100227</p> |
URL |
https://www.wjgnet.com/1007-9327/full/v31/i8/100227.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v31.i8.100227 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345